Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer.

Jiale Gao,Xiao Zhang,Zhengyang Yang,Jie Zhang,Zhigang Bai,Wei Deng,Guangyong Chen,Rui Xu,Qi Wei,Yishan Liu,Jiagang Han,Ang Li,Gang Liu,Yi Sun,Dalu Kong,Hongwei Yao,Zhongtao Zhang

Frontiers in oncology（2023）

引用 2|浏览33

暂无评分

摘要

Long-course chemoradiotherapy combined with concurrent tislelizumab in patients with locally advanced low rectal cancer had favorable safety and efficacy, and does not increase the complication rate of surgery. Further study is needed to confirm these results.

查看译文

关键词

chemoradiotherapy,combination therapy,immune checkpoint inhibitors,neoadjuvant therapy,rectal cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要